Those who take tirzepatide, the drug sold as Zepbound and Mounjaro, could lose more weight than those who take semaglutide, ...

The obesity drug helped people trim about two inches more off their waists than Wegovy in the first head-to-head study of the ...

A study of two blockbuster weight-loss drugs showed that users of Eli Lilly’s Zepbound lost just over 2 inches more off their ...

The popular weight loss medications produced different results in patients who participated in a trial, and here’s what ...

The head-to-head examination of these weight loss drugs provides doctors with 'robust' data on their effectiveness.

For the first time, a study in The New England Journal of Medicine is comparing the most popular drugs for weight loss, ...

The obesity drug helped patients reduce their waist size by an extra two inches compared to those on Novo Nordisk’s Wegovy in ...

Participants who took tirzepatide — which is sold as Zepbound by Eli Lilly — lost an average of 50 pounds over 72 weeks.

A new study has found that people taking Eli Lilly's obesity drug Zepbound lost almost 50% more weight than those using Novo ...

Eli Lilly’s weight loss drug Zepbound led to significantly greater weight loss than Novo Nordisk’s Wegovy in a 72-week, head-to-head clinical trial, according to findings published in The New England ...

Eli Lilly’s (LLY) and Novo Nordisk’s (NVO) weight loss drugs went head-to-head in a weight loss study for the first time — ...

In today’s Health Alert, two popular weight loss drugs went head-to-head in a clinical trial – and one came out on top.